AMG-51

CHF 227.00
In stock
SYN-1111-M0011 mgCHF 227.00
SYN-1111-M0055 mgCHF 461.00
SYN-1111-M01010 mgCHF 724.00
SYN-1111-M05050 mgCHF 2'173.00
SYN-1111-M100100 mgCHF 3'226.00
 
More Information
Product Details
Synonyms AMG51
Product Type Chemical
Properties
Formula C34H33F2N5O5
MW 629.7
CAS 890019-63-3
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO.
Declaration Manufactured by SynKinase.
Other Product Data Target: c-Met > mTOR | Kinase Group: Atypical (PIKK) | Substrate: Serine-Threonine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key ONSZEUCTVQJHOZ-UHFFFAOYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
c-Met kinase is the receptor for hepatocyte growth factor (HGFR). Primarily expressed on epithelial and mesenchymal cells its normal function is associated with wound healing, liver regeneration and embryo development. However, dysregulation of c-Met through overexpression, gene amplification, mutation or a ligand-dependent autocrine/paracrine loop is associated with tumorigenesis. c-Met dysregulation in human cancer patients is typically associated with a poor prognosis, aggressive disease, increased metastasis and shortened patient survival. Targeting the hepatocyte growth factor/c-Met signalling pathway as a means of cancer therapy has, therefore, become increasingly popular with a number of different therapeutic approaches undergoing clinical trials. AMG-51 represents a modified novel pyrimidone 7 compound that demonstates good effectiveness against c-Met with few off target effects at set concentrations. AMG-51 shows the enzyme selectivity of c-Met with a Ki of 4.9nM, with off target proteins such as IGFR with a Ki of 22nM, Ron with a Ki of 28nM, and KDR with Ki of 139nM.
Product References
  1. Design, synthesis, and biological evaluation of potent c-Met inhibitors: N.D. D'Angelo, et al.; J. Med. Chem. 51, 5766 (2008)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.